MIMS bulletin to highlight musculoskeletal drug 'firsts'

The next issue of MIMS Spotlight will highlight major recent drug launches in the musculoskeletal field, including the first therapeutic antibody for osteoporosis and the first new gout treatment for 40 years.

MIMS Spotlight is the latest email bulletin from MIMS, the monthly prescribing reference for primary care professionals. Each issue of the bulletin draws together essential drug news and prescribing resources for a key therapeutic area.

Coinciding with the global year against musculoskeletal pain, MIMS Spotlight on musculoskeletal conditions will profile recent drug-related developments in conditions such as arthritis, osteoporosis and gout. Alongside, it will offer a selection of helpful MIMS prescribing resources, including patient fact sheets and drug comparison tables. 

MIMS Spotlight is designed to help primary care professionals:

  • choose the right treatments
  • follow national guidelines
  • support and advise their patients
  • keep abreast of emerging medicines.

Topics covered in previous issues include summer health, women’s health and digestive disorders. Future issues will collate prescribing news and resources relevant to cardiovascular conditions, respiratory disease and other conditions commonly encountered in primary care.

To register for MIMS Spotlight, visit www.healthcarerepublic.com/bulletins.

MIMS Spotlight complements MIMS Product Update, which already provides MIMS users with a monthly email summary of new drugs and licence changes.

To register for MIMS Product Update, visit www.healthcarerepublic.com/bulletins.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus
Follow Us: